HSD17B13基因变异降低酗酒者肝硬化和肝细胞癌风险
在6171名参与者中,携带HSD17B13 rs72613567:TA与酒精相关肝硬化和肝细胞癌风险降低相关,而PNPLA3 rs738409:G则增加两者风险。HSD17B13变异可减弱PNPLA3变异相关的肝硬化风险,但对肝细胞癌的保护作用仅在男性中观察到。
要点
- HSD17B13 rs72613567:TA降低酒精相关肝硬化和肝细胞癌风险。
- PNPLA3 rs738409:G增加酒精相关肝硬化和肝细胞癌风险。
- HSD17B13变异对肝细胞癌的保护作用仅在男性中显著。
核心结论
- PNPLA3和HSD17B13变异对晚期酒精相关肝病风险有不同影响。
- 基因型/表型风险评分可能有助于该人群肝细胞癌的早期诊断。
研究设计与样本
- 对6171名参与者进行HSD17B13和PNPLA3基因分型,包括1031例酒精相关肝硬化合并肝细胞癌、1653例无肝细胞癌的酒精相关肝硬化、2588名无肝病的酗酒者和899名健康对照。
- 使用逻辑回归分析确定遗传变异与酒精相关肝硬化和肝细胞癌风险的关联。
主要发现
- 携带HSD17B13 rs72613567:TA与肝硬化风险降低相关(OR 0.79,95%CI 0.72-0.88,P=8.13×10^-6)。
- 携带HSD17B13 rs72613567:TA与肝细胞癌风险降低相关(OR 0.77,95%CI 0.68-0.89,P=2.27×10^-4)。
- 携带PNPLA3 rs738409:G与肝硬化风险增加相关(OR 1.70,95%CI 1.54-1.88,P=1.52×10^-26)。
- 携带PNPLA3 rs738409:G与肝细胞癌风险增加相关(OR 1.77,95%CI 1.58-1.98,P=2.31×10^-23)。
- 调整年龄、性别、体重指数、2型糖尿病和国家后,这些关联仍然显著。
关键数值与推荐
- HSD17B13 rs72613567:TA在男性和女性中均减弱PNPLA3 rs738409:G相关的肝硬化风险。
- HSD17B13 rs72613567:TA对后续肝细胞癌发展的保护作用仅在男性中观察到(ORallelic 0.75,95%CI 0.64-0.87,P=1.72×10^-4)。
临床怎么用
- 对酗酒者进行HSD17B13和PNPLA3基因分型可能有助于风险评估。
- 基因型/表型风险评分可能促进肝细胞癌的早期诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Carriage of rs738409:G in patatin-like phospholipase domain containing 3 (PNPLA3) is associated with an increased risk for developing alcohol-related cirrhosis and hepatocellular carcinoma (HCC). Recently, rs72613567:TA in hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) was shown to be associated with a reduced risk for developing alcohol-related liver disease and to attenuate the risk associated with carriage of PNPLA3 rs738409:G. This study explores the risk associations between these two genetic variants and the development of alcohol-related cirrhosis and HCC. APPROACH AND RESULTS: Variants in HSD17B13 and PNPLA3 were genotyped in 6,171 participants, including 1,031 with alcohol-related cirrhosis and HCC, 1,653 with alcohol-related cirrhosis without HCC, 2,588 alcohol misusers with no liver disease, and 899 healthy controls. Genetic associations with the risks for developing alcohol-related cirrhosis and HCC were determined using logistic regression analysis. Carriage of HSD17B13 rs72613567:TA was associated with a lower risk for developing both cirrhosis (odds ratio [OR], 0.79; 95% confidence interval [CI], 0.72-0.88; P = 8.13 × 10-6 ) and HCC (OR, 0.77; 95% CI, 0.68-0.89; P = 2.27 × 10-4 ), whereas carriage of PNPLA3 rs738409:G was associated with an increased risk for developing cirrhosis (OR, 1.70; 95% CI, 1.54-1.88; P = 1.52 × 10-26 ) and HCC (OR, 1.77; 95% CI, 1.58-1.98; P = 2.31 × 10-23 ). These associations remained significant after adjusting for age, sex, body mass index, type 2 diabetes, and country. Carriage of HSD17B13 rs72613567:TA attenuated the risk for developing cirrhosis associated with PNPLA3 rs738409:G in both men and women, but the protective effect against the subsequent development of HCC was only observed in men (ORallelic , 0.75; 95% CI, 0.64-0.87; P = 1.72 × 10-4 ). CONCLUSIONS: Carriage of variants in PNPLA3 and HSD17B13 differentially affect the risk for developing advanced alcohol-related liver disease. A genotypic/phenotypic risk score might facilitate earlier diagnosis of HCC in this population.
引用
- Stickel F, Lutz P, Buch S, et al. Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. Hepatology. 2020. PMID: 31630428. doi:10.1002/hep.30996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。